Nitinol Medical Technologies, Inc. v. AGA Medical Corp.

135 F. Supp. 2d 212, 49 Fed. R. Serv. 3d 833, 2000 U.S. Dist. LEXIS 20816, 2000 WL 33252102
CourtDistrict Court, D. Massachusetts
DecidedOctober 26, 2000
DocketCIV.A. 98-12506-NG
StatusPublished
Cited by8 cases

This text of 135 F. Supp. 2d 212 (Nitinol Medical Technologies, Inc. v. AGA Medical Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nitinol Medical Technologies, Inc. v. AGA Medical Corp., 135 F. Supp. 2d 212, 49 Fed. R. Serv. 3d 833, 2000 U.S. Dist. LEXIS 20816, 2000 WL 33252102 (D. Mass. 2000).

Opinion

*213 SUPPLEMENTAL MEMORANDUM AND ORDER ON PLAINTIFFS’ MOTION TO COMPEL REGARDING WAIVER OF ATTORNEY-CLIENT PRIVILEGE AND WORK PRODUCT IMMUNITY

DEIN, United States Magistrate Judge.

This Supplemental Order will address the sole issue remaining in connection with the parties’ cross-motions to' compel— namely, whether the defendant AGA Medical Corp. has waived the attorney-client privilege and its counsel’s work product immunity by asserting that it relied on the opinion of its counsel. 1 For the reasons detailed herein, unless AGA affirmatively withdraws its reliance on advice of counsel in connection with both its defense of the complaint and its counterclaims, additional materials relating to the advice given by counsel must be produced.

BACKGROUND

In its complaint filed on December 12, 1998, the plaintiffs (collectively “Nitinol”) contend that the defendant (“AGA”) infringed on plaintiffs’ Patent No. 5,108,420 (“’420 Patent”), and that such infringement was willful. AGA has answered the complaint denying infringement- and asserting as affirmative defenses that the ’420 Patent is not valid and enforceable. The defendant also has counterclaimed for a declaration of invalidity, un-enforceability, and non-infringement of the ’420 Patent.

On June 24, 1999, Nitinol served a First Request for Production of Documents and Things and First Set of Interrogatories. Interrogatory No. 10 asked AGA to:

Identify any opinion of counsel concerning the validity, enforceability, or infringement of the ’420 patent that AGA has relied upon in making, using, or selling any of the Accused Devices, state whether the opinion was oral or written, state the date upon which AGA received the opinion, identify the person(s) who rendered the opinion, identify each person to whom the opinion was directed, state whether the opinion was directed to the issue of validity, enforceability, or infringement, or to some or all of such issues, identify each person who was informed of the substance or conclusion of the opinion, and identify each person who received a copy of the opinion, if it was written.

In response, AGA objected “to the extent that the information requested is protected by the work product doctrine and attorney-client privilege” and further answered as follows:

Subject to and without waiving the general and specific objections, AGA Medical Corporation states that it has relied on the letters written by its counsel dated January 14, 1998 and January 21, 1998, both of which are being produced and made available for inspection.. The documents themselves identify the person who rendered the opinion, each person to whom the opinion was directed, whether the opinion was directed to the issue of validity, enforceability or infringement, each person who informed of the substance or conclusions of the opinion, and each person who received a copy of the opinion. Notwithstanding the above, the production of these documents should in no way be construed as *214 a waiver of attorney-client privilege related to all other matters. 2

AGA did, in fact, produce these letters of counsel to Nitinol in response to this interrogatory, although no copies have been provided to this court. It is agreed, however, that the letters were signed by one of AGA’s trial counsel. It also appears that these letters may have been produced in response to plaintiffs’ First Request for Production of Documents and Things No. 28 (“[a]ll documents relating to any contention by AGA that it has not willfully infringed the ’420 patent”) and No. 36 (“[a]ll documents relating to any opinions of counsel received by AGA with respect to the infringement, validity, or enforceability of the ’420 patent”). In response to these requests, AGA raised several general and specific objections including the objection that the request “seeks information protected by the attorney-client privilege or the attorney work product doctrine.” However, AGA continued, “[sjubject to the general and specific objections and without waiving them, responsive non-privileged documents, if any, will be produced or made available for inspection ...” at the offices of defendant’s counsel.

Nitinol contends that AGA’s decision to produce the opinions of counsel in defense of a claim of willful infringement “waives the attorney-client privilege and work product immunity with respect to other documents related to the subject matter of the opinion.” The categories of documents Nitinol is seeking from both AGA and its counsel are attached to its Supplemental Memorandum (# 77) in the form of an Exhibit to a proposed subpoena to counsel and are described infra.

AGA objects to the production of any further documents at this time. AGA contends that (1) AGA has not yet raised an advice of counsel defense and should not be called upon to do so until trial on the issue of willfulness; (2) the issue of willfulness relates to damages, and damages discovery has been severed; and (3) the scope of the requested discovery is too broad.

DISCUSSION

1. AGA Has Asserted Reliance On Advice Of Counsel

The issue of reliance on advice of counsel is a common one in patent infringement cases. That is because:

when a party learns of the existence of a patent, that party must obtain the advice of competent legal counsel before undertaking any actions that may constitute infringement. The failure to seek legal advice is a factor that supports a finding of willful infringement. Conversely, a party’s reliance on the advice of counsel is a factor that militates against a finding of willfulness.

Valois of Am., Inc. v. Risdon Corp., No. 3:95 CV 1850 AHN, 1998 WL 1661397, at *2 (D.Conn. Dec.18, 1998) (quoting Edward Lowe Indus., Inc. v. Oil-Dri Corp. of Am., No. 94 C 7568, 1995 WL 609231, at *3 (N.D.Ill. Oct.13, 1995)). As a result, the following common scenario often arises:

The current convention in patent litigation strategy is as follows: the patent owner opens with a claim for willful infringement; the alleged infringer answers by denying willful infringement and asserts good faith reliance on advice of counsel as an affirmative defense; then the owner serves contention inter *215 rogatories and document requests seeking the factual basis for that good faith reliance defense and the production of documents relating to counsel’s opinion; the alleged infringer responds by seeking to defer responses and a decision by disclosure of the opinion; the owner counters by moving to compel; and the alleged infringer moves to stay discovery and for separate trials.

Valois of Am., 1998 WL 1661397, at *3 (quoting Johns Hopkins Univ. v. CellPro, 160 F.R.D. 30, 34 (D.Del.1995)). This is substantively the scenario presented by the instant case, except that the opinion letters of counsel have already been produced.

A fair reading of AGA’s answer to Interrogatory No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Nicholas v. Bituminous Casualty Corp.
235 F.R.D. 325 (N.D. West Virginia, 2006)
Sharper Image Corp. v. Honeywell International Inc.
222 F.R.D. 621 (N.D. California, 2004)
Convolve, Inc. v. Compaq Computer Corp.
224 F.R.D. 98 (S.D. New York, 2004)
BASF AKTIENGESELLSCHAFT v. Reilly Industries, Inc.
283 F. Supp. 2d 1000 (S.D. Indiana, 2003)
Akeva L.L.C. v. Mizuno Corp.
243 F. Supp. 2d 418 (M.D. North Carolina, 2003)
Chiron Corp. v. Genentech, Inc.
179 F. Supp. 2d 1182 (E.D. California, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
135 F. Supp. 2d 212, 49 Fed. R. Serv. 3d 833, 2000 U.S. Dist. LEXIS 20816, 2000 WL 33252102, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nitinol-medical-technologies-inc-v-aga-medical-corp-mad-2000.